Skip to main content

Table 1 Power for the overall population, culture-negative patients and culture-positive patients based on the assumptions above

From: Co-trimoxazole versus azithromycin for the treatment of undifferentiated febrile illness in Nepal: study protocol for a randomized controlled trial

Total sample size in both groups (culture-positive/-negative)

All patients (ITT): power for superiority of azithromycin

Culture-negative patients: power for superiority of azithromycin

Culture-positive patients: power for “non-inferiority” of azithromycina

300 (150/150)

80%

89%

96%

300 (100/200)

92%

95%

86%

  1. aProbability that the 95% confidence interval for the effect of azithromycin excludes the possibility that azithromycin is associated with a 1.5-fold slower fever clearance time (FCT) in culture-positive patients. ITT intention-to-treat
Back to article page

Trials

ISSN: 1745-6215